BMGP, YESD, SFIO and OXGN are the Daily Market Movers for May 12th from OTCPicks.com

BIOMAGNETICS DIAGNOSTICS CORPORATION (OTC: BMGP)
Biomagnetics Diagnostics Corporation is an advanced medical device and biotechnology company and an acquirer of other innovative technologies. The Company is currently developing a waveguide-based advanced integrated optical biosensor through its cooperative research and development agreement with Los Alamos National Security, LLC, which will initially be used for cholera, tuberculosis and malaria diagnosis.

YESDTC HOLDINGS INCORPORATED (OTCBB: YESD) "Up 4.20% in morning trading"
YesDTC Holdings, Inc. is a direct-to-consumer marketing company specializing in direct response television (DRTV), Internet and retail marketing programs. The Company brings a unique set of skills to this marketplace. YesDTC combines both creative talents and financial acumen to create a total package for direct-to-consumer marketing programs. We have formed a strategic partnership with Schulberg Media Works (SMW), one of the pioneering firms in the direct-to-consumer space. SMW's track record is impressive with nearly $1 billion in revenues and a strong track record of industry awards. SMW campaigns include Tempur-Pedic, Guthy-Renker, Sony, 24-Hour Fitness, Rhino Records, HarperCollins, PureSleep, among many others.

SMOKEFREE INNOTEC INCORPORATED (OTC: SFIO) "Up 65.42% in morning trading"
Smokefree Innotec, Inc. is in the business of designing, developing, manufacturing and marketing a hi-tech, nicotine delivery cigarette-like device which is completely smoke-free and tobacco-free. Smokefree Innotec’s products are designed to protect the non-smoker from second hand smoke and all its effects while providing the smoker a way to enjoy a smoke-free cigarette anywhere, including places where smoking is prohibited. Further, our products will allow the smoker to enjoy smoking while not having to worry about the dangers and ill effects of regular cigarette smoking.

OXIGENE INCORPORATED (NASDAQ: OXGN) "Up 16.73% in morning trading"
OXiGENE, Inc. develops small-molecule therapeutics to treat cancer and eye diseases in the United States. It focuses on the development and commercialization of drug candidates that disrupt abnormal blood vessels associated with solid tumor progression and visual impairment in ocular diseases. The company's product ZYBRESTAT, is in Phase II/III pivotal registration study as a potential treatment for anaplastic thyroid cancer, as well as in Phase Ib and II clinical trials for other solid tumors, including non-small cell lung cancer, platinum resistant ovarian cancer, and head-and-neck cancer. It also develops a topical formulation of ZYBRESTAT for ophthalmological diseases and conditions, such as age-related macular degeneration. In addition, OXiGENE develops OXi4503, an ortho-quinone prodrug, which is in Phase I clinical trial for solid tumors. The company was founded in 1988 and is headquartered in Waltham, Massachusetts.

About OTCPicks.com

OTCPicks.com, one of the leading penny stock Web sites, presents its daily Stocks to Watch and Midday Market Movers every weekday. In addition to all the latest penny stock news, OTCPicks also offers daily newsletters, unique commentaries and free profiles, alerts and investing tips.

The stocks presented above are available in OTCPicks.com's Free Daily Email Newsletter. For daily penny stock alerts CLICK HERE.

Disclosure: OTCPicks has been compensated eight thousand dollars from a non-controlling third party (Emerging Market LLC) and three hundred fifty seven thousand rule 144 shares from the company for our most recent 30 day YESD advertising and promotional program. OTCPicks.com has been compensated eight thousand dollars by a third party (Emerging Markets LLC) and one hundred thirty-eight thousand restricted rule 144 shares by the company for our most recent 30-day BMGP advertising and promotional programs.